Efficacy and tolerability of low versus standard daily doses of antiseizure medications in newly diagnosed focal epilepsy. A multicenter, randomized, single‐blind, non‐inferiority trial (STANDLOW)
Sign Up to like & getrecommendations! Published in 2025 at "Epilepsia Open"
DOI: 10.1002/epi4.70016
Abstract: The STANDLOW trial investigated whether first‐line antiseizure monotherapy with low doses has a similar efficacy to standard doses, but with fewer adverse events, improved quality of life, and reduced costs for the National Health System. read more here.
Keywords: low versus; efficacy tolerability; trial; efficacy ... See more keywords
Abstract 4137942: Comparing Outcomes in Low versus High Activated Partial Thromboplastin Time-guided Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation
Sign Up to like & getrecommendations! Published in 2024 at "Circulation"
DOI: 10.1161/circ.150.suppl_1.4137942
Abstract: Introduction: Systemic anticoagulation in Extracorporeal Membrane Oxygenation (ECMO) aims to reduce the risk of patient and circuit thrombosis, but requires monitoring due to risk of bleeding. Activated partial thromboplastin time (aPTT) is one of many… read more here.
Keywords: low versus; anticoagulation; time; versus high ... See more keywords
Comparison of Low- Versus High-Dose Four-Factor Prothrombin Complex Concentrate (4F-PCC) for Factor Xa Inhibitor–Associated Bleeding: A Retrospective Study
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Intensive Care Medicine"
DOI: 10.1177/0885066620916706
Abstract: Background: Although andexanet alfa was recently approved as a specific reversal agent for apixaban and rivaroxaban, some providers still elect to administer 4-factor prothrombin complex concentrate (4F-PCC) instead, due to concerns surrounding efficacy, thrombotic risk,… read more here.
Keywords: low versus; high dose; pcc; factor ... See more keywords